Stern EK, et al. - The literature on naldemedine, the third peripherally acting μ-opioid receptor antagonists (PAMORAs), was summarized to gain US Food and Drug Administration (FDA) approval for the treatment of Opioid-induced constipation (OIC) in adults with chronic noncancer pain-related syndromes. Data suggested that for the treatment of OIC in adults with chronic noncancer pain, naldemedine could be an efficacious and safe drug.